Tumor‐Targeted Catalytic Immunotherapy
Advanced Materials · 2025-02 · 37 (5)
DOI: 10.1002/adma.202413210 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Materials, online erschienen am 15.12.2024. Verfasst von En-Li Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key…. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 380 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, National Key Research and Development Program.
Abstract (Originalsprache)
Cancer immunotherapy holds significant promise for improving cancer treatment efficacy; however, the low response rate remains a considerable challenge. To overcome this limitation, advanced catalytic materials offer potential in augmenting catalytic immunotherapy by modulating the immunosuppressive tumor microenvironment (TME) through precise biochemical reactions. Achieving optimal targeting precision and therapeutic efficacy necessitates a thorough understanding of the properties and underlying mechanisms of tumor‐targeted catalytic materials. This review provides a comprehensive and systematic overview of recent advancements in tumor‐targeted catalytic materials and their critical role in enhancing catalytic immunotherapy. It highlights the types of catalytic reactions, the construction strategies of catalytic materials, and their fundamental mechanisms for tumor targeting, including passive, bioactive, stimuli‐responsive, and biomimetic targeting approaches. Furthermore, this review outlines various tumor‐specific targeting strategies, encompassing tumor tissue, tumor cell, exogenous stimuli‐responsive, TME‐responsive, and cellular TME targeting strategies. Finally, the discussion addresses the challenges and future perspectives for transitioning catalytic materials into clinical applications, offering insights that pave the way for next‐generation cancer therapies and provide substantial benefits to patients in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Frontier…
- The Institute for Advanced Studies (IAS), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, 430079, China.
ORCID-Profile: En-Li Yang, Wu-Yin Wang, Hong Yi, Aiwen Lei, Zhi-Jun Sun
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- National Key Research and Development Program
- Interdisciplinary innovative foundation of Wuhan University
- National Key Research and Development Program of China
Zitieren
APA
Yang, E. L., Wang, W. Y., Liu, Y. Q., Yi, H., Lei, A., & Sun, Z. J. (2025). Tumor‐Targeted Catalytic Immunotherapy. Advanced Materials, 37(5). https://doi.org/10.1002/adma.202413210
Vancouver
Yang EL, Wang WY, Liu YQ, Yi H, Lei A, Sun ZJ. Tumor‐Targeted Catalytic Immunotherapy. Advanced Materials. 2025;37(5). doi:10.1002/adma.202413210
BibTeX
@article{Yang2025,
author = {Yang, En-Li and Wang, Wu-Yin and Liu, Ying-Qi and Yi, Hong and Lei, Aiwen and Sun, Zhi-Jun},
title = {Tumor‐Targeted Catalytic Immunotherapy},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {5},
doi = {10.1002/adma.202413210}
}
EUVIMED